MedTrace Logo

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

NCT02068196 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-03-24

No results posted yet for this study

Summary

The goal of this study is to understand how ipilimumab is being used, its safety profile, and the manner in which Adverse Reactions are managed in routine clinical practice. Another goal is to identify predictive biomarkers. The study is an observational study and not intended to test any hypothesis, but can be hypothesis generating.

Conditions

  • Malignant Melanoma

Interventions

PROCEDURE

Blood sampling for Pre-existing immunity

Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy

DRUG

Ipilimumab

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Tormod K Guren, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02068196 on ClinicalTrials.gov